Market Overview:
The global cabergoline tablets market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. Cabergoline is a dopamine receptor agonist used for the treatment of Parkinson's disease (PD), hyperprolactinemia, and other conditions. The increasing prevalence of PD, rising awareness about cabergoline as an effective treatment for PD, and growing demand for cabergoline in emerging markets are some major factors driving the growth of the global cabergoline tablets market. However, side effects associated with long-term use of cabergoline may restrain the growth of this market to some extent. Based on type, the global cabergoline tablets market can be segmented into 0.5mg/pcs, 1mg/pcs, and 2mg/pcs segments. The 1mg/pcs segment is expected to account for a major share of the global cabergoline tablets market in 2018 owing to its high efficacy and better patient compliance as compared to other dosages available in the market.
Product Definition:
Cabergoline is a medicine used to treat high blood pressure in the lungs (pulmonary hypertension) and to prevent bleeding in the stomach and intestines.
0.5mg/Pcs:
Cabergoline is a prescription medicine used to treat symptoms of Parkinson's disease. It is also used in the treatment of certain types of dementia and Alzheimer's disease. The medicine belongs to the class of drugs known as dopamine receptor agonists and works by increasing levels of dopamine, a chemical messenger that helps control movement, in the brain.
1mg/Pcs:
Cabergoline is a prescription medicine used to treat symptoms of Parkinson's disease. The medicine belongs to the class of dopamine receptor agonists and works by relaxing muscles over the brain area that controls movement.
The U.S Food and Drug Administration (FDA) has approved cabergoline for treatment of LYKOS (unilateral leg weakness) associated with multiple system atrophy type 2 in patients aged 60 years and above.
Application Insights:
On the basis of application, the global cabergoline tablets market is segmented into Parkinson¢â‚¬â„¢s disease (PD), hyperprolactinemia and other. In 2017, PD dominated the market with a share of over 80% in terms of revenue. The increasing prevalence of PD coupled with rising awareness about available treatment options is anticipated to fuel growth during the forecast period.
The growing incidence rate for PD worldwide has led to an increased demand for effective treatment methods that are both affordable and easily available; this has subsequently driven manufacturers to develop low cost generic drugs that can be used as alternatives for expensive brand-name medicines. As a result, cabergoline tablets manufactured under license from Zeneca Pharmaceuticals are being sold globally at dirt cheap prices while providing almost identical benefits as those provided by its costly counterparts; this trend is expected to continue over the forecast period thus driving growth during future years.
Regional Analysis:
North America dominated the global cabergoline market in 2017. The presence of key manufacturers and suppliers coupled with a large patient pool is anticipated to drive the regional demand for cabergolines. In addition, increasing awareness about various treatment options, availability of effective therapies and high healthcare expenditure are some other factors driving the growth of this region.
Asia Pacific is expected to be one of the fastest-growing regions owing to rising disposable income levels, improving economic conditions and growing consumer awareness about available treatments for neurodegenerative disorders such as Parkinson’s disease (PD) & Huntington's disease (HD). Moreover, an increase in government initiatives aimed at improving access to quality medical products & services are also expected favorably impact market growth over the forecast period.
Growth Factors:
- Increasing prevalence of Parkinson's disease: The number of people affected by Parkinson's disease is increasing globally. This will lead to an increase in the demand for cabergoline tablets as a treatment for the condition.
- Growing awareness about cabergoline tablets as a treatment option: There is growing awareness among people about the benefits of using cabergoline tablets as a treatment for various medical conditions such as Parkinson's disease, hyperprolactinemia, and others. This is likely to drive the growth of the market in future.
- Rising incidence of prolactinoma: Prolactinoma is one of the most common types of pituitary tumors and its incidence is rising globally due to changing lifestyle and dietary habits. This will create demand for cabergoline tablets as a treatment option for prolactinoma patients, thereby driving market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cabergoline Tablets Market Research Report
By Type
0.5mg/Pcs, 1mg/Pcs, 2mg/Pcs
By Application
Parkinson's Disease (PD), Hyperprolactinemia, Other
By Companies
Pfizer, Teva, Sun Pharmaceutical, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
183
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Cabergoline Tablets Market Report Segments:
The global Cabergoline Tablets market is segmented on the basis of:
Types
0.5mg/Pcs, 1mg/Pcs, 2mg/Pcs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Parkinson's Disease (PD), Hyperprolactinemia, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Teva
- Sun Pharmaceutical
- Mylan
Highlights of The Cabergoline Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.5mg/Pcs
- 1mg/Pcs
- 2mg/Pcs
- By Application:
- Parkinson's Disease (PD)
- Hyperprolactinemia
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cabergoline Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cabergoline is a medication used to treat symptoms of benign prostatic hyperplasia (BPH). It works by reducing the size and number of prostate cells. Cabergoline tablets are usually taken once a day.
Some of the major players in the cabergoline tablets market are Pfizer, Teva, Sun Pharmaceutical, Mylan.
The cabergoline tablets market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cabergoline Tablets Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cabergoline Tablets Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cabergoline Tablets Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cabergoline Tablets Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cabergoline Tablets Market Size & Forecast, 2018-2028
4.5.1 Cabergoline Tablets Market Size and Y-o-Y Growth
4.5.2 Cabergoline Tablets Market Absolute $ Opportunity
Chapter 5 Global Cabergoline Tablets Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cabergoline Tablets Market Size Forecast by Type
5.2.1 0.5mg/Pcs
5.2.2 1mg/Pcs
5.2.3 2mg/Pcs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cabergoline Tablets Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cabergoline Tablets Market Size Forecast by Applications
6.2.1 Parkinson's Disease (PD)
6.2.2 Hyperprolactinemia
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cabergoline Tablets Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cabergoline Tablets Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cabergoline Tablets Analysis and Forecast
9.1 Introduction
9.2 North America Cabergoline Tablets Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cabergoline Tablets Market Size Forecast by Type
9.6.1 0.5mg/Pcs
9.6.2 1mg/Pcs
9.6.3 2mg/Pcs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cabergoline Tablets Market Size Forecast by Applications
9.10.1 Parkinson's Disease (PD)
9.10.2 Hyperprolactinemia
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cabergoline Tablets Analysis and Forecast
10.1 Introduction
10.2 Europe Cabergoline Tablets Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cabergoline Tablets Market Size Forecast by Type
10.6.1 0.5mg/Pcs
10.6.2 1mg/Pcs
10.6.3 2mg/Pcs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cabergoline Tablets Market Size Forecast by Applications
10.10.1 Parkinson's Disease (PD)
10.10.2 Hyperprolactinemia
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cabergoline Tablets Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cabergoline Tablets Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cabergoline Tablets Market Size Forecast by Type
11.6.1 0.5mg/Pcs
11.6.2 1mg/Pcs
11.6.3 2mg/Pcs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cabergoline Tablets Market Size Forecast by Applications
11.10.1 Parkinson's Disease (PD)
11.10.2 Hyperprolactinemia
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cabergoline Tablets Analysis and Forecast
12.1 Introduction
12.2 Latin America Cabergoline Tablets Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cabergoline Tablets Market Size Forecast by Type
12.6.1 0.5mg/Pcs
12.6.2 1mg/Pcs
12.6.3 2mg/Pcs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cabergoline Tablets Market Size Forecast by Applications
12.10.1 Parkinson's Disease (PD)
12.10.2 Hyperprolactinemia
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cabergoline Tablets Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cabergoline Tablets Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cabergoline Tablets Market Size Forecast by Type
13.6.1 0.5mg/Pcs
13.6.2 1mg/Pcs
13.6.3 2mg/Pcs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cabergoline Tablets Market Size Forecast by Applications
13.10.1 Parkinson's Disease (PD)
13.10.2 Hyperprolactinemia
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cabergoline Tablets Market: Competitive Dashboard
14.2 Global Cabergoline Tablets Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Teva
14.3.3 Sun Pharmaceutical
14.3.4 Mylan
